Thus, to study the potential efficacy of picolog in an in vivo model with direct clinical implications, we selected the conditional transgenic model of a rapidly progressive lymphoma arising from MYC overexpression in the lymphoid compartment [34-41]. Here, MYC is linked to lymphoma.